Oxford, UK - NeoVac, a leading pharmaceutical company specialising in innovative lipid nanoparticle (LNP) technologies for mRNA therapeutics, is pleased to announce the appointment of Dr. Jan H. Egberts as Chief Executive Officer to guide the next phase of growth for the company

 

Over the past four years, NeoVac has transformed from a scientific concept into a clinically validated platform poised for scale. Dr. Egberts brings a successful track record in biotech company leadership, including previous roles as CEO, board chair and investor across both private and publicly listed healthcare companies. His strategic and operational expertise will be instrumental as NeoVac enters its next stage of growth.

 

Egberts shared, “As one of the earliest investors in the company, I have a long-held belief in NeoVac’s vision for transforming RNA delivery through NeoVac’s proprietary LNP 2.0 platform featuring clinically validated improved safety. I look forward to working closely with our exceptional team to accelerate development programs and expand global access to our technology.”

 

Egberts has over 25 years of experience in the pharmaceutical and medtech industries, most recently as the CEO of his own family office, Veritas Investment.  Veritas Investments owns eight medical device and medical services companies throughout Europe as well as minority equity positions in more than 10 privately held healthcare companies. Dr Egberts is past chair of ViroClinics, (sold to Serba), Photocure ASP, and Nordic Nanovector ASP.  Dr Egberts currently serves on the supervisory Board of the European Nuclear Reactor Group for Medical Isotopes, NRG / Pallas, as well as a number of privately held companies and foundations.  Prior to Veritas Investments, Dr Egberts served as CEO of OctoPlus, which he sold to Dr Reddy’s, Agendia as well as an operating advisor for 3i Group.  He graduated from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford, after which he worked as a management consultant for McKinsey. 

 

NeoVac’s proprietary platform technology addresses critical limitations of conventional delivery systems, allowing engineering of tailored LNPs for a broad scope of applications in vaccination and therapy. Based on a versatile lipid library, LNPs with tunable immune activation and targeting specificity at the cellular level can be engineered. A recently completed clinical study demonstrated improved safety compared to licensed products, together with a proven humoral and cellular response for vaccination. With this, NeoVac technology holds promise to be advantageous compared to existing systems for further clinical development of mRNA vaccines and therapeutics.

 

Relevant Publications

 

The Pharma Letter

 

FirstWord Pharma

 

Pharmafile

 

Fierce Biotech

 

Bio World

 

STAT News